QEP: Nucleic Acid Detection System For Non-Viral Microorganism(S) Causing Sexually Transmitted Infections

Product code QEP, “Nucleic Acid Detection System For Non-Viral Microorganism(S) Causing Sexually Transmitted Infections” in FDA's classification database, is a Class II device type under 21 CFR 866.3393 (device to detect nucleic acids from non-viral microorganism(s) causing sexually transmitted infections and associated resistance marker(s)), reviewed by FDA's Microbiology panel. FDA's 510(k) database lists 24 clearances under QEP, 24 of them since 2011.
Updated Oct 29, 2026 · Clearances from FDA’s 510(k) database, as of Oct 29, 2026
Product code
QEP
Regulation
21 CFR 866.3393
Class
II
Panel
Microbiology
Clearances
24
Most recent
Jul 8, 2026
Median review, last 2 years
171 days
Third-party review
Not eligible
Implant
No

What it covers

A device to detect nucleic acids from non-viral microorganism(s) causing sexually transmitted infections is an in vitro diagnostic device intended for the detection and identification of nucleic acids from non-viral microorganism(s) in clinical specimens collected from patients suspected of sexually transmitted infections. The device is intended to aid in the diagnosis of non-viral sexually transmitted infections in conjunction with other clinical and laboratory data.

FDA’s definition of product code QEP, from the Product Classification database.

Recent clearances

510(k)DeviceApplicantDecisionType
K260917cobas CT/NG for use on the cobas 5800/6800/8800 systems; cobas TV/MG for use on the cobas 5800/6800/8800 systemsRoche Molecular Systems, Inc.Jul 8, 2026Traditional
K253756cobas liat CT/NG nucleic acid testRoche Molecular Systems, Inc.May 15, 2026Dual Track
K253759cobas liat CT/NG/MG nucleic acid testRoche Molecular Systems, Inc.May 15, 2026Dual Track
K251501Visby Medical Men's Sexual Health TestVisby Medical, Inc.Oct 1, 2025Dual Track
K243343BD CTGCTV2Bd Integrated Diagnostic Solutions/Becton,Apr 22, 2025Traditional
K240217cobas® liat CT/NG nucleic acid testRoche Molecular Systems, Inc.Jan 17, 2025Dual Track
K240197cobas® liat CT/NG/MG nucleic acid testRoche Molecular Systems, Inc.Jan 16, 2025Dual Track
K230267NeuMoDx CT/NG Assay 2.0Neumodx Molecular, Inc.Dec 22, 2023Traditional
K220407Visby Medical Sexual Health TestVisby MedicalMar 7, 2023Dual Track
K222379Alinity m STI AssayAbbott Molecular, Inc.Mar 3, 2023Traditional
From FDA’s 510(k) database, as of Oct 29, 2026Export CSV (100 rows free · all 24 with a free account)

Clearances by year

24 QEP 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.

YearClearancesMedian days to decision
2026 (so far)3171
20254268
20233325
20223438
20213521
2020346
2019587

Who submits

11 applicants cleared a QEP device since 2011. 100% of the clearances went to applicants in United States. By type: Traditional 54%, Dual Track 29%, Special 13% and Direct 4%.

ApplicantClearances since 2011
Roche Molecular Systems, Inc.7
Hologic, Inc.5
Abbott Molecular, Inc.2
Binx Health, Inc.2
Visby Medical2
Bd Integrated Diagnostic Solutions/Becton,1
Becton, Dickinson and Company1
Cepheid1

How FDA classifies it

Class II (special controls). The special controls for this device are:

(1) The intended use for the labeling required under § 809.10 of this chapter must include a detailed description of targets the device detects, the results provided to the user, the clinical indications appropriate for test use, and the specific population(s) for which the device is intended.

(2) Any sample collection device used must be FDA-cleared, -approved, or -classified as 510(k) exempt (standalone or as part of a test system) for the collection of specimen types claimed by this device; alternatively, the sample collection device must be cleared in a premarket submission as a part of this device.

(3) The labeling required under § 809.10(b) of this chapter must include:

(i) A detailed device description, including reagents, instruments, ancillary materials, all control elements, and a detailed explanation of the methodology, including all pre-analytical methods for processing of specimens;

(ii) Detailed discussion of the performance characteristics of the device for all claimed specimen types based on analytical studies, including Limit of Detection, inclusivity, cross-reactivity, interfering substances, competitive inhibition, carryover/cross contamination, specimen stability, within lab precision, and reproducibility, as appropriate;

(iii) Detailed descriptions of the test procedure, the interpretation of test results for clinical specimens, and acceptance criteria for any quality control testing;

(iv) Limiting statements indicating that:

(A) A negative test result does not preclude the possibility of infection;

(B) The test results should be interpreted in conjunction with other clinical and laboratory data available to the clinician;

(C) Reliable results are dependent on adequate specimen collection, transport, storage, and processing. Failure to observe proper procedures in any one of these steps can lead to incorrect results; and

(D) If appropriate (e.g., recommended by the Centers for Disease Control and Prevention, by current well-accepted clinical guidelines, or by published peer reviewed research), that the clinical performance is inferior in a specific clinical subpopulation or for a specific claimed specimen type; and

(v) If the device is intended to detect antimicrobial resistance markers, limiting statements, as appropriate, indicating that:

(A) Negative results for claimed resistance markers do not indicate susceptibility of detected microorganisms, as resistance markers not measured by the assay or other potential mechanisms of antibiotic resistance may be present;

(B) Detection of resistance markers cannot be definitively linked to specific microorganisms and the source of a detected resistance marker may be an organism not detected by the assay, including colonizing flora;

(C) Detection of antibiotic resistance markers may not correlate with phenotypic gene expression; and

(D) Therapeutic failure or success cannot be determined based on the assay results, since nucleic acid may persist following appropriate antimicrobial therapy.

(4) Design verification and validation must include:

(i) Detailed device description documentation, including methodology from obtaining sample to result, design of primer/probe sequences, rationale for target sequence selection, and computational path from collected raw data to reported result (e.g., how collected raw signals are converted into a reported result).

(ii) Detailed documentation of analytical studies, including, Limit of Detection, inclusivity, cross-reactivity, microbial interference, interfering substances, competitive inhibition, carryover/cross contamination, specimen stability, within lab precision, and reproducibility, as appropriate.

(iii) Detailed documentation and performance results from a clinical study that includes prospective (sequential) samples for each claimed specimen type and, when determined to be appropriate by FDA, additional characterized clinical samples. The study must be performed on a study population consistent with the intended use population and compare the device performance to results obtained from FDA accepted comparator methods. Documentation from the clinical studies must include the clinical study protocol (including a predefined statistical analysis plan) study report, testing results, and results of all statistical analyses.

(iv) A detailed description of the impact of any software, including software applications and hardware-based devices that incorporate software, on the device's functions.

From 21 CFR 866.3393. Special controls are the requirements a 510(k) must show it meets.

Standards

21 CFR 866.3393 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent QEP clearances declared.

Ask about QEP

US FDA devices: 510(k), De Novo, guidance, 21 CFR

Questions about QEP

What is FDA product code QEP?

Product code QEP, “Nucleic Acid Detection System For Non-Viral Microorganism(S) Causing Sexually Transmitted Infections” in FDA's classification database, is a Class II device type under 21 CFR 866.3393 (device to detect nucleic acids from non-viral microorganism(s) causing sexually transmitted infections and associated resistance marker(s)), reviewed by FDA's Microbiology panel. FDA's 510(k) database lists 24 clearances under QEP, 24 of them since 2011.

How many 510(k) clearances are there under QEP?

FDA’s 510(k) database listed 24 clearances under QEP as of Oct 29, 2026, 24 of them decided since 2011; the most recent decision was Jul 8, 2026. The Predicate Finder searches the live database.

How long does FDA take to clear a QEP 510(k)?

For the 7 QEP clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 171 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.

Which companies have the most QEP clearances?

Since 2011: Roche Molecular Systems, Inc. (7), Hologic, Inc. (5), Abbott Molecular, Inc. (2), Binx Health, Inc. (2) and Visby Medical (2). 11 applicants have cleared a QEP device in that time.

Sources

  1. FDA product classification: QEP · Product Classification database
  2. 21 CFR 866.3393: Device to detect nucleic acids from non-viral microorganism(s) causing sexually transmitted infections and associated resistance marker(s) · eCFR, as of Oct 27, 2026
  3. openFDA 510(k) query for QEP · run Oct 29, 2026
  4. 510(k) Premarket Notification database · FDA, accessdata.fda.gov
Follow QEPGet an email when FDA clears, recalls or publishes guidance for QEP devices.

Know what FDA already cleared.